Close Menu

NEW YORK (GenomeWeb) – Sialix said this week that it has raised an additional $2 million as part of its Series B round, bringing the total raised to $6 million.

The company also said that it has changed its name to Siamab Therapeutics, marking its shift from a glycomics-focused firm to one focused on developing therapeutic antibodies for cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.